research Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
Ritlecitinib effectively regrows hair in severe alopecia areata, especially in adolescents.
Search
for
Sort by
Research
150-180 / 556 results research 186 Mechanistic insights into Ritlecitinib-mediated immunomodulation in Alopecia Areata
research 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
research A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
research Current best evidence in pigmentary dermatology
Several treatments are effective for pigmentary disorders like vitiligo and melasma.
research A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
Ritlecitinib is safe and may effectively treat alopecia areata.
research Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
research Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
research Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.
research Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
research Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial
Hair regrowth in Alopecia Areata patients leads to increased satisfaction and reduced stress.
research Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
research Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment
Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.
research Off-Label Treatment of Alopecia Areata—Retrospective Study
Off-label treatments are heavily used for alopecia areata due to limited approved options.
research Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
research Case Report: Alopecia areata in an adolescent after COVID-19 infection
COVID-19 may trigger hair loss conditions like alopecia areata.
research Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark
Alopecia areata patients have higher risks of infections, lymphoma, heart issues, and death.
research Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study
Baricitinib is effective and safe for treating severe alopecia areata.
research Research progress in the treatment of non-scarring alopecia: mechanism and treatment
New treatments are needed for non-scarring alopecia due to current limitations.
research Effects of Natural Herbal Marker Compounds on Human Dermal Papilla Cell Growth Regulation
Four natural compounds were found to promote hair growth effectively.
research Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
Ritlecitinib effectively treats alopecia areata with manageable side effects.
research Unlocking the Potential of Rosemary in Alopecia: A Narrative Review of Evidence on Mechanism, Applications and Challenges
Rosemary shows promise in treating alopecia, similar to minoxidil, but more research is needed.
research Microneedle-Mediated Transdermal Drug Delivery for the Treatment of Multiple Skin Diseases
Microneedles improve drug delivery for skin diseases, enhancing treatment effectiveness and patient compliance.
research Alopecia areata
research The Diverse Experiences and Challenges of Individuals With Alopecia Areata: Survey Results From Finland
Alopecia areata greatly affects quality of life, with many experiencing mental health issues and lacking professional support.
research The first 20 years of skin of color dermatology: An era of advancements in skin, hair, and nail disorders
Significant progress has been made in treating skin, hair, and nail disorders in people with skin of color, but disparities still exist.
research Hydrogel forming microneedles loaded with VEGF and Ritlecitinib/polyhydroxyalkanoates nanoparticles for mini-invasive androgenetic alopecia treatment
New microneedle treatment with growth factors and a hair loss drug shows better and faster hair growth results than current treatments.